218 related articles for article (PubMed ID: 27795504)
1. [Dendritic cell and cancer immune checkpoint].
Kubo T; Hirohashi Y; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(5):468-472. PubMed ID: 27795504
[TBL] [Abstract][Full Text] [Related]
2. [Immune-related adverse events of immune checkpoint inhibitors].
Tadano H; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
4. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Hahn AW; Gill DM; Pal SK; Agarwal N
Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
[TBL] [Abstract][Full Text] [Related]
5. Cancer Immunotherapy Targeting Co-signal Molecules.
Nakajima M; Tamada K
Adv Exp Med Biol; 2019; 1189():313-326. PubMed ID: 31758539
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors: a new frontier in bladder cancer.
Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
[TBL] [Abstract][Full Text] [Related]
8. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
[TBL] [Abstract][Full Text] [Related]
9. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
10. The expanding role of immunotherapy.
Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
[TBL] [Abstract][Full Text] [Related]
11. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
12. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
13. Immunological and clinical implications of immune checkpoint blockade in human cancer.
Kim HD; Park SH
Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
[TBL] [Abstract][Full Text] [Related]
14. The immune checkpoint inhibitors: where are we now?
Webster RM
Nat Rev Drug Discov; 2014 Dec; 13(12):883-4. PubMed ID: 25345674
[No Abstract] [Full Text] [Related]
15. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
Versteven M; Van den Bergh JMJ; Marcq E; Smits ELJ; Van Tendeloo VFI; Hobo W; Lion E
Front Immunol; 2018; 9():394. PubMed ID: 29599770
[TBL] [Abstract][Full Text] [Related]
16. [Era of cancer immunotherapy has come].
Nakatsura T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):164-71. PubMed ID: 27320931
[TBL] [Abstract][Full Text] [Related]
17. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Blockade in Cancer Therapy.
Postow MA; Callahan MK; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
[TBL] [Abstract][Full Text] [Related]
19. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Lee JY; Lee HT; Shin W; Chae J; Choi J; Kim SH; Lim H; Won Heo T; Park KY; Lee YJ; Ryu SE; Son JY; Lee JU; Heo YS
Nat Commun; 2016 Oct; 7():13354. PubMed ID: 27796306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
